Related Experiment Video
Updated: Jun 19, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies
Raffaella Dell'Eva1, Claudia Ambrosini, Nicola Vannini
1Molecular Oncology, National Institute for Cancer Research, Genova, Italy.
Background:
Leukemias are dependent on Akt/NF-kappaB activation and angiogenesis.
Methods:
The antiangiogenic Akt/NF-kappaB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.
Results:
Inhibition of cell proliferation is associated with induction of apoptosis and reduced VEGF secretion. Decreased cell invasion, metalloprotease production, and adhesion to endothelial cells observed in the presence of XN could prevent in vivo life-threatening complications of leukostasis and tissue infiltration.
Conclusions:
As endothelial cells and hematopoietic cells are mutually correlated in their development and growth, targeting both tumor cells and endothelial cells with agents possessing cytotoxic and antiangiogenic activities may lead to synergistic antitumor effects interrupting a reciprocal stimulatory loop between leukemia and endothelial cells.
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

